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Vein graft stenosis has been the focus of much vascular 
research since it was first systematically described 
by Imparato in 1972, although Carrel had noted the 
phenomenon in experimental studies undertaken in 
the early years of this century. Recently interest in 
vein graft stenosis has been rather overshadowed by 
the concentration fresearch on restenosis after arterial 
angioplasty. Substantial similarities exist between 
post-angioplasty restenosis and vein graft stenosis: the 
incidence of both conditions is around 25-40% of 
all cases with no very clearly definable risk factors. 
Histologically the major feature is intimal hyperplasia 
and the predominant cytological component is the 
proliferating vascular smooth muscle cell and its se- 
creted matrix. The following comments are mostly 
drawn from angioplasty restenosis data but, to some 
degree, they will probably be applicable to vein graft 
stenosis. 
Research into restenosis has followed a predictable 
pattern. After initial screening assessing the effect on 
smooth muscle cells in culture an agent is tested in an 
animal model of vascular injury. This is normally 
balloon injury to the endothelium of the rat carotid 
artery. Promising results are followed by similar ex- 
periments in a larger animal. If activity against the 
smooth muscle cell proliferative response to injury is 
confirmed, the agent is then investigated in a human 
trial. This is usually in restenosis after coronary an- 
gioplasty. Quantitative angiography is used to measure 
the outcome of the angioplasty with a re-study 6-12 
months later. In all such trials (and to date there are 
nearly 70 published studies and probably an equal 
number of unpublished ones) agents uch as heparins, 
aspirin, warfarin, ACE inhibitors, statins, steroids, fish 
oils, and numerous others, have universally failed to 
make an impact on the incidence of coronary re- 
stenosis. 
Success admits few interpretations, failure admits 
many. Explanations for this puzzling disparity be- 
tween animal models and human disease are legion: 
maybe the agent works, but not in the doses or re- 
gimens that can be given to humans (a singularly 
unhelpful explanation); maybe quantitative angio- 
graphy is too much concerned with millimetres and 
not enough with clinical utility; maybe normal vessels 
in young animals ubjected to injury behave differently 
from diseased vessels in elderly humans, and many 
more. 
Surely there have been studies that have shown 
positive results in preventing restenosis? There have 
been such studies, but due to major design faults, these 
reports have never gained much credit. A recurring 
problem has been the use of an inferred endpoint, 
with restenosis diagnosed without angiographic on- 
firmation; an exercise which has been repeatedly 
shown to be unreliable. In this context, it is interesting 
to note the widespread notion that the platelet integrin 
receptor antagonist abciximab, (ReoPro) 1 is active 
against restenosis, when the study contains no an- 
giographic measurement a all. 
Could smooth muscle cell proliferation be the wrong 
target? Other components contributing to restenosis 
are elastic recoil after arterial stretching and con- 
strictive remodelling. Remodelling is an interesting 
concept, first demonstrated by Glagov as com- 
pensatory enlargement of the lumen in the presence 
of eccentric atherosclerotic plaque. Studies using intra- 
vascular ultrasound in coronary arteries have shown 
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that a decrease in the cross-sectional rea of the whole 
artery might be a more important contributor to re- 
stenosis than an increase in the cross-sectional rea of 
the arterial wall. 2 The mechanisms responsible for this 
phenomenon have not been adequately addressed; 
experimental studies have implicated roles for ad- 
ventitial constrictive scarring, for vessel wall cell apo- 
ptosis and for extracellular matrix remodelling, all 
termed together as "vascular emodelling". There has 
not been any confirmation of a major role for vascular 
remodelling in restenosis in human histological 
samples. 
Vascular emodelling after angioplasty certainly oc- 
curs, and is likely to contribute to restenosis, par- 
ticularly in small arteries subject o deep wall injury 
but seems less likely to contribute to vein conduit 
restenoses. An approach to reduce the impact of elastic 
recoil and constrictive remodelling is the use of intra- 
vascular stents. 
Two large trials of coronary stenting have shown a 
definite decrease in restenosis. However, this decrease 
is rather moderate, from around 35% to around 25%. 3,4 
The nature of stent efficacy is interesting. The devices 
appear to excite more smooth muscle proliferation 
and intimal hyperplasia. However, this produces less 
luminal restenosis because of the greater initial gain 
in diameter from stent deployment. The longer term 
implications of greater smooth muscle cell pro- 
liferation are not known, but the use of coronary 
Palmaz stents appear to be associated with benign 
outcomes even 4-6 years post-insertion, s 
What about other new vascular devices? Restenosis 
complicates all high technology methods of re- 
vascularisation and results are not so favourable as 
stents. Laser angioplasty has no advantage over con- 
ventional angioplasty and may in fact precipitate a
greater rate of restenosis. 6 Atherectomy in the coronary 
arteries or in the femoropopliteal segment has not 
been shown to reduce restenosis compared to an- 
gioplasty and again may result in a greater ate Of 
restenosis. 7,8 
What therefore are the prospects for the inhibition 
of restenosis after angioplasty and bypass grafting? 
Firstly, I must complain about the relative paucity 
of studies in bypass grafting. Lower limb bypass is 
common, the stenosis rate of around 25-30% is sig- 
nificant, follow-up is often complete and objective 
assessment of stenosis is available with duplex scan- 
ning in most vascular centres, obviating the need for 
invasive angiographic re-study. In purely theoretical 
terms the bypass graft has considerable advantages 
for study, as there is no pre-existing stenosis and vessel 
wall injury is minor in comparison to angioplasty. This 
renders the bypass graft a "cleaner" model for study, 
certainly in respect of agents proposed to have activity 
against smooth muscle cell proliferation. Additionally 
there is an important echnical advantage; measure- 
ment error of quantitative angiography or ultrasound 
is dependent on equipment rather than on whether 
coronary or peripheral segments are being imaged. 
This error therefore represents a smaller coefficient of 
variation in larger peripheral arteries than in smaller 
coronary vessels. 
The prospects for prevention of bypass graft re- 
stenosis are uncertain. Moody et al.'s findings that there 
was no part of a vein conduit that was particularly 
susceptible to graft stenosis, and that stenosis could 
not be related to sites of valves or clamp injury re- 
inforces the view that improvements in surgical tech- 
nique are unlikely to affect restenosis. 9 Some agents 
shown to be ineffective in coronary restenosis might 
prove effective in graft restenosis, due to the po- 
tentially different roles of remodelling and intimal 
hyperplasia in the two situations. Progress in this area 
depends on the energy of vascular esearchers and the 
entrepreneurial spirit of the pharmaceutical industry 
(which has sadly been somewhat dented by the lack 
of progress thus far). 
The prospects for prevention of angioplasty re- 
stenosis, by contrast, reflects substantial activity in 
this field for 10 years. New devices appear to have 
disappointing effects, as have drugs with other cardio- 
vascular actions. Stents have demonstrated a proven, 
though modest improvement in restenosis. Further 
trials are building upon this finding by seeking im- 
provements in instrumentation, stent design and im- 
pregnation of stent material with heparin and possibly 
other agents which might be active against smooth 
muscle cell proliferation. Very preliminary results from 
a heparin bonded stent trial in coronary disease have 
shown restenosis rates in single figures, but these 
figures need to be interpreted cautiously. 1°
In the longer term, the prospects for restenosis pre- 
vention will depend on greater understanding of the 
molecular mechanisms ofrestenosis. The gene therapy 
approach to restenosis represents a realistic research 
tool to dissect out the molecular pathways involved 
in smooth muscle cell hyperplasia. In my view, the 
insertion of human nucleotides into the vascular wall 
to prevent a complication that rarely leads to life or 
limb loss without warning symptoms is not justified. 
I would modify this position to state that such therapy 
might be justified in the future should adult genetic 
manipulation be shown to be safe, effective and with- 
out major side effects. However, the model situations 
to demonstrate this are likely to be in cancer rather 
than in vascular disease. 
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Local pharmacology holds more promise in the 
restenosis field. High concentrations of active agents 
can be delivered in prolonged release preparations, or
bonded to stents at the site of vascular intervention. 
This is logistically simpler in the context of surgical 
bypass than in angioplasty. Advances on this front 
may lead to revisiting trials of agents previously in- 
effective in systemic doses. A logical extension of this 
concept, localised beta irradiation as cytostatic therapy, 
is under investigation. 
Restenosis research is a prime example of the failure 
of empiricism. The investigation of drugs useful in 
other areas of cardiovascular medicine, on the as- 
sumption that encouraging findings in simple animal 
models would translate into human efficacy has been 
a spectacular and expensive failure, for a variety of 
reasons. I suggest hat the vascular clinician should 
lead the regrouping of research effort in this area 
by the promotion of human peripheral bypass and 
angioplasty as the best models for further study. 
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